Reproductive Biology and Endocrinology (Apr 2012)

GnRH agonist versus GnRH antagonist in <it>in vitro</it> fertilization and embryo transfer (IVF/ET)

  • Depalo Raffaella,
  • Jayakrishan K,
  • Garruti Gabriella,
  • Totaro Ilaria,
  • Panzarino Mariantonietta,
  • Giorgino Francesco,
  • Selvaggi Luigi E

DOI
https://doi.org/10.1186/1477-7827-10-26
Journal volume & issue
Vol. 10, no. 1
p. 26

Abstract

Read online

Abstract Several protocols are actually available for in Vitro Fertilization and Embryo Transfer. The review summarizes the main differences and the clinic characteristics of the protocols in use with GnRH agonists and GnRH antagonists by emphasizing the major outcomes and hormonal changes associated with each protocol. The majority of randomized clinical trials clearly shows that in “in Vitro” Fertilization and Embryo Transfer, the combination of exogenous Gonadotropin plus a Gonadotropin Releasing Hormone (GnRH) agonist, which is able to suppress pituitary FSH and LH secretion, is associated with increased pregnancy rate as compared with the use of gonadotropins without a GnRH agonist. Protocols with GnRH antagonists are effective in preventing a premature rise of LH and induce a shorter and more cost-effective ovarian stimulation compared to the long agonist protocol. However, a different synchronization of follicular recruitment and growth occurs with GnRH agonists than with GnRH antagonists. Future developments have to be focused on timing of the administration of GnRH antagonists, by giving a great attention to new strategies of stimulation in patients in which radio-chemotherapy cycles are needed.

Keywords